Extracellular Vesicle MicroRNA and Its Use

JP2025519331A5Pending Publication Date: 2026-06-16UNIVERSITY OF VERMONT +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
UNIVERSITY OF VERMONT
Filing Date
2023-06-06
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Current MSC-based therapies for diseases such as ischemic stroke, myocardial infarction, and ARDS have variable results in human clinical studies, indicating a need for new approaches to enhance therapeutic efficacy.

Method used

A method for generating an EV-miRNA profile by adding an activating factor to MSC cultures, using miRNA sequencing to identify miRNAs associated with MSC-EVs, and creating a profile based on the presence or absence of each miRNA compared to a control, which can be used to identify candidates for MSC-based therapy.

Benefits of technology

This approach allows for the identification of specific miRNAs that regulate the paracrine response of MSCs, potentially improving the therapeutic efficacy of MSC-based therapies by tailoring treatment to specific diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Compositions comprising miRNA (MSC-EV-miRNA) derived from mesenchymal stromal cell-derived extracellular vesicles and their use in subjects diagnosed with acute respiratory distress syndrome (ARDS) and other inflammatory diseases are disclosed herein. Also disclosed herein are methods for creating differential MSC-EV-miRNA profiles for any disease of interest (e.g., ARDS) and the use of miRNA profiles for creating miRNA-based therapies. Additional aspects of the disclosure relate to primer mixes for rapidly detecting specific miRNA profiles, and kits thereof.
Need to check novelty before this filing date? Find Prior Art